Sunderland, United Kingdom, November 12, 2010 --(PR.com
)-- Experts in the provision of solid-state chemistry services for the pharmaceutical and biotech industries, leading global contract research organisation, Onyx Scientific, is delighted to report increased demand in taking candidate compounds from concept through to process development and scale-up of APIs for Phase I and Phase II clinical studies.
“Handling difficult-to-crystallize materials is an art form as well as a science,” explains Tony Flinn, CEO, Onyx Scientific. “Inherently complicated, the implications of a well-designed crystallization process are considerable and it requires exceptional scientific knowledge to reliably isolate products in a crystalline phase. Through diverse chemistry expertise we take candidate compounds through all stages of solid-form characterization, salt selection, co-crystal and polymorph screening in the challenge to develop optimum crystal forms.”
“Equally, in the world of polymorphs, confusing results come as standard,” explains Tony. “Our high-throughput polymorph screening platform requires just milligram amounts of target material to evaluate APIs for polymorphisms.”
Tony adds, “The demand for our solid-state contract chemistry services has never been stronger.”
Onyx solid-state chemistry services typically include:
· Polymorph, salt, and co-crystal screening and investigation
· Amorphous content and stability investigations
· Physico-chemical characterization and selection of the optimal solid form
· Crystallization screening and process optimization
As ‘preferred supplier’ to four of the world’s top seven pharmaceutical companies, Onyx also enjoys repeat business with more than 150 companies worldwide.